Ra Medical Systems Announces Platinum Partnership with OEIS: Demonstrating Commitment to Deliver High-Quality Care in Office ...
May 14 2019 - 9:01AM
Business Wire
Ra Medical Systems, Inc. (NYSE: RMED) today announced its
investment to support high quality patient care in Office
Interventional Suites through its Platinum Partnership, the highest
level of commitment, with the Outpatient Endovascular and
Interventional Society (OEIS). Ra Medical Systems was recognized
for its shared vision and financial contribution at the OEIS 6th
annual national meeting in St. Petersburg, FL.
“We believe patient care through Office Interventional Suites
(OIS) is the future of endovascular medicine, and we share OEIS’
mission of innovation, evidence-based outcomes, and patient
safety,” said Dean Irwin, CEO, Ra Medical Systems. “We are
dedicated to providing physicians a better way to treat patients
and grow their practice. I am thrilled to announce our further
investment through this Platinum Partnership.”
One of only three Platinum Partners, Ra Medical Systems has
demonstrated an ongoing commitment to OEIS, and its investment will
promote learning opportunities and collaboration to advance the
practice of medicine in an OIS. The partnership will provide Ra
Medical Systems with increased access and visibility to the OEIS
leadership and member vascular surgeons, interventional
radiologists, cardiologists, and other specialists involved in
office-based endovascular procedures.
At the OEIS annual meeting on April 5-6, 2019, Athar Ansari, MD,
Director of California Heart & Vascular Clinic in El Centro,
CA, spoke on the important role OIS serve in providing quality
patient care in rural areas. He stated, “DABRA is a critical tool
for me to meet the need for safe, high-quality treatments. It
avoids the complications of other devices, and I have experienced
DABRA to be effective where other devices have failed.” During his
podium session at OEIS, Dr. Ansari presented data that demonstrated
a 94% success rate, and no distal embolization, in a study of 200
patients treated with DABRA.
DABRA (Destruction of Arteriosclerotic Blockages by laser
Radiation Ablation) is a novel, minimally invasive excimer laser
system that non-thermally, photochemically ablates channels in
vascular blockages. Unlike many mechanical, acoustic, or thermal
treatments for peripheral artery disease that may damage the
arterial wall, DABRA treats blockages with minimal vascular
trauma.
Dr Ansari concluded, “By incorporating DABRA into my office
interventional suite, I can spare patients hospital stays and
reduce costs to the healthcare system.”
About Ra Medical Systems
Ra Medical Systems is a commercial medical device company
developing and marketing innovative excimer laser systems for the
treatment of vascular and dermatologic diseases. DABRA launched in
2017 for the endovascular treatment of blockages resulting from
lower extremity vascular disease. Pharos launched in 2004 for the
treatment of dermatological disorders including psoriasis,
vitiligo, and atopic dermatitis. DABRA and Pharos are based on Ra
Medical’s core excimer laser technology platform that produces 308
nanometer light, a UVB wavelength that studies have demonstrated
increases T-cell apoptosis, or cell death, which may produce a
beneficial, targeted immunosuppressive effect. Ra Medical
manufactures DABRA and Pharos excimer lasers and catheters in a
32,000-square-foot facility located in Carlsbad, California. The
vertically integrated facility is ISO 13485 certified and is
licensed by the state of California to manufacture sterile,
single-use catheters in controlled environments.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements generally relate to future events
or Ra Medical's future financial or operating performance. In some
cases, you can identify forward-looking statements because they
contain words such as "may," "will," "should," "expects," "plans,"
"anticipates," "could," "intends," "target," "projects,"
"contemplates," "believes," "estimates," "predicts," "potential" or
"continue" or the negative of these words or other similar terms or
expressions that concern Ra Medical's future expectations,
strategy, plans or intentions. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the potential benefits to patients and physicians using the DABRA
catheter and laser system. Ra Medical's expectations and beliefs
regarding these matters may not materialize, and actual results in
future periods are subject to risks and uncertainties that could
cause actual results to differ materially from those projected or
implied by such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of DABRA and Pharos and procedures performed using such devices by
physicians, payors, and other third parties; development and
acceptance of new products or product enhancements; clinical and
statistical verification of the benefits achieved via the use of Ra
Medical’s products; the Company’s ability to effectually manage
inventory; Ra Medical’s ability to recruit and retain management
and key personnel; Ra Medical’s need to comply with complex and
evolving laws and regulations; intense and increasing competition
and consolidation in Ra Medical’s industry; the impact of rapid
technological change; costs and adverse results in any ongoing or
future legal proceedings; adverse outcome of regulatory
inspections; and the other risks and uncertainties described in Ra
Medical’s news releases and filings with the Securities and
Exchange Commission. Information on these and additional risks,
uncertainties, and other information affecting Ra Medical's
business and operating results is contained in Ra Medical’s
quarterly report on Form 10-Q for the quarter ended March 31, 2019
and in its other filings with the Securities and Exchange
Commission. The forward-looking statements in this press release
are based on information available to Ra Medical as of the date
hereof, and Ra Medical disclaims any obligation to update any
forward-looking statements, except as required by law.
Ra Medical investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (www.ramed.com), our
investor relations website (https://ir.ramed.com/), press releases,
SEC filings, and public conference calls in order to achieve broad,
non-exclusionary distribution of information to the public and to
comply with our disclosure obligations under Regulation FD. We
encourage our investors and others to monitor and review the
information we make public in these locations as such information
could be deemed to be material information. Please note that this
list may be updated from time to time.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190514005301/en/
Media ContactsCaitlin Kasunich / Lisa LipsonKCSA
Strategic Communications212.896.1241 /
508.843.6428ckasunich@kcsa.com / llipson@kcsa.com
Investor ContactJeffrey KrawsPresident, Ra Medical
Systems760.707.7516investorrelations@ramed.com
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ra Medical Systems (NYSE:RMED)
Historical Stock Chart
From Apr 2023 to Apr 2024